This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jonathan Davidson, MD
Department of Psychiatry Veterans Administration Medical Center Fulton Street Durham, NC 27705 David Raft, MD Department of Psychiatry University of North Carolina School of Medicine Chapel Hill, NC 27514

Arch Gen Psychiatry. 1985;42(6):635-636.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Two recent studies have shown that monoamine oxidase (MAO) inhibitors are more effective than controlled treatments in depression that is associated with atypical vegetative symptoms of hyperphagia and weight gain. In one study¹ isocarboxazid was superior to placebo early in treatment, and in another study phenelzine was superior to imipramine and placebo.² Patients with depression and atypical vegetative symptoms have been poorly characterized in previous studies of classification and treatment response. Since they may have a specifically good response to MAO inhibitors, it is obviously important that these patients be identified and better described.

Earlier,^3,4 we reported that phenelzine was superior to amitriptyline and placebo in patients with chronic pain and depression. To our knowledge, this was the first report of an MAO inhibitor being more effective than a tricyclic antidepressant. Since analgesic use was minimal in the study, we do not believe that . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?